Loading stock data…
NYXH
$3.00+0.02 (+0.67%)
Market ClosedLast close May 1
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA).
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Nyxoah SA in the Healthcare sector is trading at $3.00. The stock is currently near its 52-week low of $2.76, remaining 39.4% below its 200-day moving average. Technical signals show neutral RSI of 52 and bullish MACD crossover, explaining why NYXH maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 52) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$3.00
Potential Upside
5%
Whystock Fair Value$3.15
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company's lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$134.04M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.87
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-183.36%
Volume
Today's trading volume
5,213
Recent News
Baird Lowers its Price Target on Nyxoah SA (NYXH) to $4.62 from $5.87
Nyxoah SA (NASDAQ:NYXH) is one of the 7 Fastest Growing European Stocks to Invest In. On March 23, 2026, Baird analyst David Rescott lowered the price target on Nyxoah SA (NASDAQ:NYXH) to $4.62 from $5.87 and maintained a Neutral rating, citing model updates as the company’s U.S. rollout begins to gain traction but remains in […]
Nyxoah Details Early U.S. Genio Launch, Reimbursement Update at Oppenheimer MedTech Conference 2026
Nyxoah (NASDAQ:NYXH) used its presentation at Oppenheimer’s MedTech and Services Conference 2026 to outline the company’s early U.S. launch progress for its Genio system, a neuromodulation therapy for obstructive sleep apnea (OSA), and to address investor questions around reimbursement and operating
Nyxoah SA (NYXH) Q4 2025 Earnings Call Highlights: U.S. Launch Success and Financial Challenges
Nyxoah SA (NYXH) reports strong U.S. launch momentum for Genio despite increased operating losses and cash burn concerns.
Nyxoah (NYXH) Q4 2025 Earnings Call Transcript
During the call, we will discuss our operating activities and review our fourth quarter 2025 financial results released after U.S. market close today, after which we will host a question and answer session. Before we begin, I would like to remind you that any statements that relate to expectations or predictions of future events, market trends, results, or performance are forward-looking statements. All forward-looking statements are based upon our current estimates and various assumptions.
Nyxoah Q4 Earnings Call Highlights
Nyxoah (NASDAQ:NYXH) used its fourth-quarter and full-year 2025 earnings call to outline the first results from the U.S. launch of its Genio hypoglossal nerve stimulation system, discuss the evolving reimbursement environment for the category, and provide initial growth expectations for early 2026.